Loading
IBI363 is an experimental fusion protein from Innovent Biologics (Suzhou) in phase 2 trials for melanoma, non-small-cell lung cancer and colorectal cancer, aimed at PD-1.
IBI363 is a fusion protein developed by Innovent Biologics (Suzhou). Its target is PD-1 (the sponsor names IL-2 pathway x PD-1). The sponsor states: A mutated IL-2 cytokine fused to an anti-PD-1 antibody, combining IL-2 pathway stimulation with PD-1 checkpoint blockade in a single molecule. ClinicalTrials.gov describes the intervention as: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in melanoma, non-small-cell lung cancer, colorectal cancer and renal cell carcinoma. The largest, NCT06797297, plans to enrol 180 participants with primary completion was scheduled for 2026-03-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A mutated IL-2 cytokine fused to an anti-PD-1 antibody, combining IL-2 pathway stimulation with PD-1 checkpoint blockade in a single molecule. Connects to PD-1.
1.IBI363 binds PD-1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IBI363" OR ABSTRACT:"IBI363") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IBI363, not a curated reading list.
Shares Renal cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Melanoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-1, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Innovent Biologics, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Melanoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.